Cue biopharma announces appointment of patricia nasshorn as chief business officer

Cambridge, mass., dec. 15, 2021 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted t cells directly within the patient's body, announced today the appointment of patricia nasshorn, as chief business officer, effective december 15th, 2021.
CUE Ratings Summary
CUE Quant Ranking